Clinical trial tests first-in-class bifunctional immunotherapy drug in HPV-associated cancers


HPV-16 E5 Oncoprotein

Patients with HPV-associated malignancies may be eligible to participate in a new clinical trial at the NIH Clinical Center.

There are more than 100 varieties of human papillomavirus (HPV). Most HPV infections cause warts to grow on different parts of the body, but some types of HPV infections can cause cancer in multiple areas of the body. HPV-associated cancers that spread or do not respond to treatment are often incurable. Julius Strauss, M.D., of the Laboratory of Tumor Immunology and Biology is testing an experimental drug called M7824, a first-in-class bifunctional immunotherapy. In previous studies, M7824 simultaneously blocked two molecular pathways that cancer cells use to evade the immune system. The goal of this study is to see if M7824 can control the growth of HPV-associated tumors by restoring and improving the immune system’s ability to kill cancer cells.   

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Tue, 05/01/2018